BPG is committed to discovery and dissemination of knowledge
Featured Articles
4/27/2020 10:40:04 AM | Browse: 479 | Download: 512
Publication Name World Journal of Clinical Oncology
Manuscript ID 52802
Country/Territory United States
Received
2019-12-30 14:08
Peer-Review Started
2019-12-30 14:13
To Make the First Decision
Return for Revision
2020-02-20 06:07
Revised
2020-03-25 23:54
Second Decision
2020-03-27 07:59
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2020-03-30 01:42
Articles in Press
2020-03-30 01:42
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2020-04-22 06:13
Publish the Manuscript Online
2020-04-22 10:32
ISSN 2218-4333 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Medicine, Research & Experimental
Manuscript Type Review
Article Title Narrowing the focus: Therapeutic cell surface targets for refractory triple-negative breast cancer
Manuscript Source Invited Manuscript
All Author List Narges K Tafreshi, David L Morse and Marie Catherine Lee
Funding Agency and Grant Number
Corresponding Author Marie Catherine Lee, FACS, MD, Surgeon, Surgical Oncologist, Comprehensive Breast Program, Moffitt Cancer Center, 12920 N. McKinley Drive, Tampa, FL 33612, United States. m.catherine.lee@moffitt.org
Key Words Breast cancer; Triple negative; Biomarker; Cell surface; Targeted therapy; Chemorefractory
Core Tip Triple-negative breast cancer continues to be a challenge in breast cancer therapeutics, as these heterogeneous tumors are refractory to many effective and well-tolerated standard treatments. Even more concerning is the subpopulation of these tumors that progress even on the most aggressive therapeutic regimens. The core of this work reviews the developing approaches for treatment-refractory triple-negative breast cancer and proposes cell-surface targeting as a novel modality for targeted treatment of resistant disease.
Publish Date 2020-04-22 10:32
Citation Tafreshi NK, Morse DL, Lee MC. Narrowing the focus: Therapeutic cell surface targets for refractory triple-negative breast cancer. World J Clin Oncol 2020; 11(4): 169-179
URL https://www.wjgnet.com/2218-4333/full/v11/i4/169.htm
DOI https://dx.doi.org/10.5306/wjco.v11.i4.169
Full Article (PDF) WJCO-11-169.pdf
Full Article (Word) WJCO-11-169.docx
Manuscript File 52802-Review.docx
Answering Reviewers 52802-Answering reviewers.pdf
Audio Core Tip 52802-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 52802-Conflict-of-interest statement.pdf
Copyright License Agreement 52802-Copyright license agreement.pdf
Peer-review Report 52802-Peer-review(s).pdf
Scientific Misconduct Check 52802-Scientific misconduct check.pdf
Scientific Editor Work List 52802-Scientific editor work list.pdf